GlassScriptPhysician profile
Ana Katrina Endaya
NPI 1962802124
$5,408.61
in general payments reported to CMS, 2019-2025
27 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,481 · 2022: $1,787 · 2023: $1,004 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,140.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,013.72 | 2021-2023 | Farxiga, Breztri |
| Abbvie INC. | $617.65 | 2021-2022 | |
| Glaxosmithkline, LLC. | $576.58 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $473.95 | 2021-2023 | Rybelsus, Ozempic, Tresiba |
| Bayer Healthcare Pharmaceuticals INC. | $326.48 | 2021-2023 | |
| Lilly USA, LLC | $298.51 | 2022-2023 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.91 | 2021-2023 | Jardiance, Stiolto Respimat |
| Sanofi-Aventis U.S. LLC | $273.37 | 2021-2022 | |
| Dexcom, INC. | $250.78 | 2022-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $213.57 | 2021 | |
| Pfizer INC. | $188.62 | 2021-2023 | |
| Esperion Therapeutics, INC. | $171.42 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $121.39 | 2021 | |
| Novartis Pharmaceuticals Corporation | $83.51 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.53 | 2022-2023 | Xifaxan |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $69.25 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $66.33 | 2022 | |
| Amgen INC. | $57.20 | 2022-2023 | Repatha, Otezla |
| Abbott Laboratories | $47.15 | 2021-2022 | |
| Exact Sciences Corporation | $43.71 | 2023 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $30.06 | 2021-2023 | Eliquis |
| Amarin Pharma, INC. | $28.91 | 2022 | |
| Merck Sharp & Dohme LLC | $27.71 | 2021 | |
| Daiichi Sankyo INC. | $25.67 | 2023 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $17.72 | 2021 | |
| Seqirus USA INC | $17.51 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Intuity Medical INC | $13.40 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Endaya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.